Dataset Information


Polymorphisms in CYP2C9 are associated with response to indomethacin among neonates with patent ductus arteriosus.

ABSTRACT: BackgroundPatent ductus arteriosus (PDA) is a common complication seen in preterm infants. Indomethacin is routinely used to treat PDA. Evidence suggests that the response of indomethacin is highly heritable. This study investigated the association between single-nucleotide polymorphisms (SNPs) in CYP2C9 and the closure of PDA in response to indomethacin.MethodsSix SNPs in CYP2C9 were analyzed for association with indomethacin response. A case-control analysis was performed among neonates who responded to indomethacin (responders) and among those who required surgical ligation (non-responders). Independent transmission disequilibrium tests were performed among parent-child trios of responders and non-responders.ResultsThe G allele of rs2153628 was associated with increased odds of response to indomethacin in the case-control analysis (odds ratios (OR): 1.918, 95% confidence interval (CI): 1.056, 3.483). Among indomethacin responders, the G allele of rs2153628 and the T allele of rs1799853 were overtransmitted from the parents to their child (OR: 2.667, 95% CI: 1.374, 5.177 and OR: 2.375, 95% CI: 1.040, 5.425, respectively), consistent with the case-control analysis.ConclusionWe identified an association between two SNPs in CYP2C9, rs2153628 and rs1799853, and indomethacin response for the treatment of PDA. These findings suggest that response to indomethacin in the closure of PDA may be influenced by polymorphisms associated with altered indomethacin metabolism.

PROVIDER: S-EPMC5645220 | BioStudies |

REPOSITORIES: biostudies

Similar Datasets

| S-EPMC2925896 | BioStudies
| S-EPMC6817966 | BioStudies
| S-EPMC6704716 | BioStudies
| S-EPMC5654678 | BioStudies
| S-EPMC7196482 | BioStudies
| S-EPMC5056586 | BioStudies
2018-01-01 | S-EPMC5885871 | BioStudies
| S-EPMC8194770 | BioStudies
| S-EPMC3779671 | BioStudies
| S-EPMC3529799 | BioStudies